tiprankstipranks
Immuron Limited’s Travelan Sales Surge Globally
Company Announcements

Immuron Limited’s Travelan Sales Surge Globally

Immuron Limited (AU:IMC) has released an update.

Don't Miss our Black Friday Offers:

Immuron Limited reports robust sales growth for its gastrointestinal supplement Travelan, with a 13% increase globally in the September 2024 quarter, led by a significant 48% rise in North America and steady growth in Australia. The company continues to expand its market presence, securing additional pharmacy group partnerships in Australia and increasing distribution channels across North America and Canada.

For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskImmuron Limited Showcases Promising Biopharmaceutical Innovations
TipRanks Australian Auto-Generated NewsdeskImmuron Limited Secures Approval on Key AGM Resolutions
TipRanks Australian Auto-Generated NewsdeskImmuron Limited Sees Record Sales and Positive Trial Developments
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App